Free Access
Med Sci (Paris)
Volume 19, Number 5, Mai 2003
Page(s) 613 - 619
Section M/S Revues
Published online 15 May 2003
  1. Forno LS. The Lewy body in Parkinson’s disease. Adv Neurol 1987; 45: 35–43. [Google Scholar]
  2. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979–80. [Google Scholar]
  3. Lansbury PT, Brice A. Genetics of Parkinson’s disease and biochemical studies of implicated gene products. Curr Opin Genet Dev 2002; 12: 299–306. [Google Scholar]
  4. Lotharius J, Brundin P. Pathogenesis of Parkinson’s disease: dopamine, vesicles and alphasynuclein. Nat Rev Neurosci 2002; 3: 932–42. [Google Scholar]
  5. Kahle PJ, Haass C, Kretzschmar HA, Neumann M/S n° 5, vol. 19, mai 2003 M. Structure/function of alpha-synuclein in health and disease: rational development of animal models for Parkinson’s and related diseases. J Neurochem 2002; 82: 449–57. [Google Scholar]
  6. Spillantini MG, Schmidt ML, Lee VM, et al. Alphasynuclein in Lewy bodies. Nature 1997; 388: 839–40. [Google Scholar]
  7. Kirik D, Rosenblad C, Burger C, et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 2002; 22: 2780–91. [Google Scholar]
  8. Klein RL, King MA, Hamby ME, Meyer EM. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum Gene Ther 2002; 13: 605–12. [Google Scholar]
  9. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P. Alphasynucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease. Proc Natl Acad Sci USA 2002; 99: 10813–8. [Google Scholar]
  10. Xu J, Kao SY, Lee FJ, et al. Dopamine-dependent neurotoxicity of alphasynuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002; 8: 600–6. [Google Scholar]
  11. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopaminealpha- synuclein adduct. Science 2001; 294: 1346–9. [Google Scholar]
  12. Conway KA, Lee SJ, Rochet JC, et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alphasynuclein mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 2000; 97: 571–6. [Google Scholar]
  13. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002; 418: 291. [Google Scholar]
  14. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitinprotein ligase. Nat Genet 2000; 25: 302–5. [Google Scholar]
  15. Shimura H, Schlossmacher MG, Hattori N, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science 2001; 293: 263–9. [Google Scholar]
  16. Giasson BI, Lee VM. Parkin and the molecular pathways of Parkinson’s disease. Neuron 2001; 31: 885–8. [Google Scholar]
  17. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson’s disease susceptibility. Cell 2002; 111: 209–18. [Google Scholar]
  18. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256–9. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.